You searched for "VEGF"
Initiatives in macular service provision
A report from Monitor in October 2015 identifies good practices that will realise most of the potential productivity gain in elective care available to NHS hospitals. These include: stratifying patients by risk and creating low-complexity pathways for lower-risk patients (tailoring...
FA findings in treatment-naive premature infants
This retrospective study examined fluorescein angiography (FA) images of 162 eyes of 81 treatment-naive infants with retinal vascular immaturity and persistent avascular retina (PAR) despite exceeding postmenstrual age of 60 weeks. Disc diameter (DD), optic disc-to-fovea distance (FD), the length...
International variations in ROP treatment
A retrospective cohort review of 48,087 premature infants weighing <1500 gm between 24 to 27 weeks gestation, from 11 high income countries in Australia, New Zealand, Canada, Finland, Israel, Japan, Spain, Sweden, Switzerland, Tuscany (Italy) and the UK . By...
ANGPTL-4 inhibition reduces inflammation in diabetic retinopathy
Diabetic retinopathy (DR) is the most common cause of blindness in working-age humans, and numbers are rising due to increased cases of type 2 diabetes (T2D). T2D is associated with increased obesity and dyslipidaemia, which is a major risk factor...
How many injections in nAMD: ranibizumab vs. aflibercept
Intravitreal anti-VEGF injections make up a large proportion of the workload in ophthalmology clinics. Since the introduction of aflibercept with eight weekly injections there has been an option to use a treatment which may require less treatment, with potential cost...
Intravitreal functional plasminogen in branch retinal vein occlusion
Branch retinal vein occlusion (BRVO) is the second most common vascular disorder of the eye. Intravitreal injections of anti-VEGF agents and corticosteroids have proven efficacy. Posterior vitreous cortex (PVC) adhesion has been shown to support the development of retinal vein...
Effect of single intravitreal injection of bevacizumab on contrast sensitivity in patients with central retinal vein occlusion
Central retinal vein occlusion is the second most common retinal vascular disorder after diabetic retinopathy. There are many studies reporting the efficacy of intravitreal anti-VEGF injections for macular oedema secondary to retinal vein occlusions. This paper looks at the contrast...Hot debates in medical retina and imaging: Perspectives from the Controversies in Ophthalmology 2020 virtual conference
Controversies in medical retina and imaging were debated during the Controversies in Ophthalmology 2020 virtual conference held during two mid-day scientific sessions on 27 and 28 March 2020. The author recounts key perspectives and presents viewpoint recommendations from the Vision...Renewed momentum in ocular gene and cell therapy, broadening application to chronic disease
Gene and cell therapies offer the prospect of ground-breaking new avenues for the treatment of diseases, reflected in a renewed explosion of interest and investment in retinal gene therapy. Rod McNeil reports recent clinical trial readouts across a diverse range...Treatment of diabetic macular oedema
Diabetic macular oedema (DMO) is a common complication associated with diabetic retinopathy, and the most common cause of visual impairment in diabetes [1]. With predicted rising levels of diabetes (in England by 2025 the estimated population with diabetes will be...
Data update for leading causes of CVI in England and Wales
In this article the authors present an epidemiological update, based on certifiable visual impairment (CVI) registration for figures for sight impairment (SI) in England and Wales from the last report of 2007-2008 to the current data for April 2012 to...
